Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Po-Shen KoYuan-Bin YuYao-Chung LiuYi-Tsui WuMan-Hsin HungJyh-Pyng GauChia-Jen LiuLiang-Tsai HsiaoPo-Min ChenTzeon-Jye ChiouChun-Yu LiuJin-Hwang LiuPublished in: Current medical research and opinion (2017)
This finding highlights the significance of anemia in CML-CP, and suggests that patients with anemia at diagnosis should be carefully monitored and might benefit from more potent TKIs if not achieving 3M-EMR.